Shopping Cart 0
Cart Subtotal
AED 0

Retinal Vein Occlusion - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Retinal Vein Occlusion-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion-Pipeline Review, H2 2018, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 4, 1, 9, 1 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 4

Retinal Vein Occlusion-Overview 5

Retinal Vein Occlusion-Therapeutics Development 6

Retinal Vein Occlusion-Therapeutics Assessment 11

Retinal Vein Occlusion-Companies Involved in Therapeutics Development 19

Retinal Vein Occlusion-Drug Profiles 29

Retinal Vein Occlusion-Dormant Projects 94

Retinal Vein Occlusion-Discontinued Products 95

Retinal Vein Occlusion-Product Development Milestones 96

Appendix 108


List Of Figure

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H2 2018 9

Number of Products under Development by Companies, H2 2018 10

Number of Products by Top 10 Targets, H2 2018 14

Number of Products by Stage and Top 10 Targets, H2 2018 14

Number of Products by Top 10 Mechanism of Actions, H2 2018 16

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 16

Number of Products by Routes of Administration, H2 2018 18

Number of Products by Stage and Routes of Administration, H2 2018 18

Number of Products by Molecule Types, H2 2018 20

Number of Products by Stage and Molecule Types, H2 2018 20


List Of Table

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Retinal Vein Occlusion-Pipeline by 3SBio Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Addmedica SAS, H2 2018

Retinal Vein Occlusion-Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Annexin Pharmaceuticals AB, H2 2018

Retinal Vein Occlusion-Pipeline by Cell Medica Ltd, H2 2018

Retinal Vein Occlusion-Pipeline by Celon Pharma SA, H2 2018

Retinal Vein Occlusion-Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018

Retinal Vein Occlusion-Pipeline by Clearside BioMedical Inc, H2 2018

Retinal Vein Occlusion-Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Eyevensys SAS, H2 2018

Retinal Vein Occlusion-Pipeline by Formycon AG, H2 2018

Retinal Vein Occlusion-Pipeline by Gene Signal International SA, H2 2018

Retinal Vein Occlusion-Pipeline by Graybug Vision Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Lupin Ltd, H2 2018

Retinal Vein Occlusion-Pipeline by Mabion SA, H2 2018

Retinal Vein Occlusion-Pipeline by Novartis AG, H2 2018

Retinal Vein Occlusion-Pipeline by Ocular Therapeutix Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Ohr Pharmaceutical Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Oxurion NV, H2 2018

Retinal Vein Occlusion-Pipeline by Profarma, H2 2018

Retinal Vein Occlusion-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion-Dormant Projects, H2 2018

Retinal Vein Occlusion-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Retinal Vein Occlusion Therapeutic Products under Development, Key Players in Retinal Vein Occlusion Therapeutics, Retinal Vein Occlusion Pipeline Overview, Retinal Vein Occlusion Pipeline, Retinal Vein Occlusion Pipeline Assessment


Companies

3SBio Inc

Addmedica SAS

Aerie Pharmaceuticals Inc

Annexin Pharmaceuticals AB

Cell Medica Ltd

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

EyeGate Pharmaceuticals Inc

Eyevensys SAS

Formycon AG

Gene Signal International SA

Graybug Vision Inc

Lupin Ltd

Mabion SA

Novartis AG

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Oxurion NV

Profarma

Regeneron Pharmaceuticals Inc

Retinal Vein Occlusion-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion-Pipeline Review, H2 2018, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 4, 1, 9, 1 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 4

Retinal Vein Occlusion-Overview 5

Retinal Vein Occlusion-Therapeutics Development 6

Retinal Vein Occlusion-Therapeutics Assessment 11

Retinal Vein Occlusion-Companies Involved in Therapeutics Development 19

Retinal Vein Occlusion-Drug Profiles 29

Retinal Vein Occlusion-Dormant Projects 94

Retinal Vein Occlusion-Discontinued Products 95

Retinal Vein Occlusion-Product Development Milestones 96

Appendix 108


List Of Figure

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H2 2018 9

Number of Products under Development by Companies, H2 2018 10

Number of Products by Top 10 Targets, H2 2018 14

Number of Products by Stage and Top 10 Targets, H2 2018 14

Number of Products by Top 10 Mechanism of Actions, H2 2018 16

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 16

Number of Products by Routes of Administration, H2 2018 18

Number of Products by Stage and Routes of Administration, H2 2018 18

Number of Products by Molecule Types, H2 2018 20

Number of Products by Stage and Molecule Types, H2 2018 20


List Of Table

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Retinal Vein Occlusion-Pipeline by 3SBio Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Addmedica SAS, H2 2018

Retinal Vein Occlusion-Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Annexin Pharmaceuticals AB, H2 2018

Retinal Vein Occlusion-Pipeline by Cell Medica Ltd, H2 2018

Retinal Vein Occlusion-Pipeline by Celon Pharma SA, H2 2018

Retinal Vein Occlusion-Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018

Retinal Vein Occlusion-Pipeline by Clearside BioMedical Inc, H2 2018

Retinal Vein Occlusion-Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Eyevensys SAS, H2 2018

Retinal Vein Occlusion-Pipeline by Formycon AG, H2 2018

Retinal Vein Occlusion-Pipeline by Gene Signal International SA, H2 2018

Retinal Vein Occlusion-Pipeline by Graybug Vision Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Lupin Ltd, H2 2018

Retinal Vein Occlusion-Pipeline by Mabion SA, H2 2018

Retinal Vein Occlusion-Pipeline by Novartis AG, H2 2018

Retinal Vein Occlusion-Pipeline by Ocular Therapeutix Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Ohr Pharmaceutical Inc, H2 2018

Retinal Vein Occlusion-Pipeline by Oxurion NV, H2 2018

Retinal Vein Occlusion-Pipeline by Profarma, H2 2018

Retinal Vein Occlusion-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Retinal Vein Occlusion-Dormant Projects, H2 2018

Retinal Vein Occlusion-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Retinal Vein Occlusion Therapeutic Products under Development, Key Players in Retinal Vein Occlusion Therapeutics, Retinal Vein Occlusion Pipeline Overview, Retinal Vein Occlusion Pipeline, Retinal Vein Occlusion Pipeline Assessment


Companies

3SBio Inc

Addmedica SAS

Aerie Pharmaceuticals Inc

Annexin Pharmaceuticals AB

Cell Medica Ltd

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

EyeGate Pharmaceuticals Inc

Eyevensys SAS

Formycon AG

Gene Signal International SA

Graybug Vision Inc

Lupin Ltd

Mabion SA

Novartis AG

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Oxurion NV

Profarma

Regeneron Pharmaceuticals Inc